Longitudinal evaluation of serial ctDNA kinetics using joint modeling in patients with metastatic breast cancer
Tracking blood cancer DNA levels over time—not just once—provides updated survival predictions that could help doctors adjust treatment plans more responsively.
This NPJ Precis Oncol study applies joint modeling of longitudinal-survival data to serial ctDNA tumor fraction measurements in 49 mBC patients, finding that continuously updated TF estimates strongly predict both OS and time to treatment discontinuation. This approach moves beyond static biomarker snapshots to provide dynamically updated prognoses that could support real-time clinical decision-making.
What the study was
- Study design
- Prospective biomarker study with joint longitudinal modeling
- Population
- HR+/HER2- metastatic breast cancer on endocrine therapy + CDK4/6 inhibitor
- Sample size
- 49
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- NPJ Precis Oncol
Why it surfaced
Methodologically innovative (joint modeling for ctDNA) in NPJ Precis Oncol. n=49 is small; Guardant Health involvement. Value as methodology-building paper.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.